India-based global pharma company Lupin Limited (BSE: 500257) (NSE: LUPIN) announced on Friday the US launch of Risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial, and 50 mg per vial, Single-Dose Vials, with 180-day CGT exclusivity.
This follows the recent approval from the US Food and Drug Administration (FDA).
The product is Lupin's first using proprietary technology from PrecisionSphere, the long-acting injectable (LAI) platform developed by its subsidiary Nanomi B.V.
PrecisionSphere technology creates uniform microspheres that deliver extended-release profiles from weeks to months, superior injectability through smaller needles, and consistent drug concentrations. Lupin is expanding the reach of its PrecisionSphere technology through collaborations with companies looking to extend their product lifecycles.
BioInvent secures EMA positive opinion for Orphan Drug Designation of BI-1808 in CTCL
Lupin launches Risperidone long-acting injectable with 180-day CGT exclusivity in US market
BodyLogicMD supports recommendation to remove black box warnings on certain forms of oestrogen
Fondazione Telethon reports positive opinion for Waskyra marketing authorisation in Europe
Maxx Orthopedics Receives FDA 510(k) Clearance for Its Libertas® Bipolar Hip System
CHMP issues positive opinion for DAWNZERA in hereditary angioedema
Merck to acquire Cidara Therapeutics in USD9.2bn deal to expand antiviral portfolio
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
Ascletis Pharma announces ASC36 and ASC35 co-formulation for clinical development
EirGenix signs second global exclusive licensing deal with Sandoz